EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anatomical Outcomes After Focal Laser Photocoagulation for Central Serous Chorioretinopathy: An Exploratory Retrospective Study

Gamze Ucan Gunduz iD, Mehmet Omer Kiristioglu iD

Journal of Clinical Medicine · 31.10.2026 · 15 (21) · 8482

DOI: 10.3390/jcm15218482 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 31.10.2026. Verfasst von Gamze Ucan Gunduz und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Faculty of Medicine, Bursa Uludağ University, 16059 Bursa, Turkey. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Focal laser photocoagulation (FLP) remains an option for nonresolving central serous chorioretinopathy (CSCR) with discrete extrafoveal leakage, but response-associated factors are incompletely characterized. We evaluated anatomical and functional outcomes and imaging correlates after treatment.

Methods

This retrospective single-center study included 49 eyes of 47 patients with symptoms lasting at least 6 months. Angiography-guided laser targeted leakage sites more than 250 µm from the foveal center. The primary outcome was complete subretinal fluid (SRF) resolution at Month 3. Associations were assessed using Firth logistic regression, including a post hoc Month-1 landmark analysis.

Results

Complete SRF resolution occurred in 26/49 eyes (53.1%) at Month 1, 38/49 (77.6%; 95% CI, 63.4–88.2%) at Month 3, and 35/49 (71.4%) at Month 6; 34/49 (69.4%) achieved sustained Month-3/Month-6 resolution. Month-3 rates were 93.5%, 75.0%, and 30.0% for single focal leakage, multiple focal leakage, and slow ooze, respectively (age- and sex-adjusted global Holm-adjusted p = 0.006) according to fundus fluorescein angiography. Among 23 eyes with residual SRF at Month 1, greater baseline-to-Month-1 central macular thickness reduction was associated with subsequent Month-3 resolution (OR per 100 µm = 7.15; 95% CI, 1.78–121.29; Holm-adjusted p = 0.003). Serous pigment epithelial detachment was associated with lower odds of sustained response (aOR = 0.13; 95% CI, 0.02–0.64; Holm-adjusted p = 0.037). Best-corrected visual acuity improved through Month 6 (estimated change, −0.137 logMAR; Holm-adjusted p = 0.002), and no secondary choroidal neovascularization was detected.

Conclusions

Month-3 SRF resolution was frequent in this selected treated cohort. Imaging associations were exploratory and require validation in larger controlled cohorts. The uncontrolled design precludes attribution of resolution solely to FLP, and 6-month follow-up does not establish long-term safety.

Schlagwörter

Stichwörter der Autor:innen

central serous chorioretinopathyfluorescein angiographyfocal laser photocoagulationoptical coherence tomographypigment epithelial detachmentsubretinal fluid

Autor:innen und Institutionen

  • Department of Ophthalmology, Faculty of Medicine, Bursa Uludağ University, 16059 Bursa, Turkey.

ORCID-Profile: Gamze Ucan Gunduz, Mehmet Omer Kiristioglu

Zitieren

APA

Ucan Gunduz, G., & Kiristioglu, M. O. (2026). Anatomical Outcomes After Focal Laser Photocoagulation for Central Serous Chorioretinopathy: An Exploratory Retrospective Study. Journal of Clinical Medicine, 15(21), 8482. https://doi.org/10.3390/jcm15218482

Vancouver

Ucan Gunduz G, Kiristioglu MO. Anatomical Outcomes After Focal Laser Photocoagulation for Central Serous Chorioretinopathy: An Exploratory Retrospective Study. Journal of Clinical Medicine. 2026;15(21):8482. doi:10.3390/jcm15218482

BibTeX
@article{UcanGunduz2026,
  author = {Ucan Gunduz, Gamze and Kiristioglu, Mehmet Omer},
  title = {Anatomical Outcomes After Focal Laser Photocoagulation for Central Serous Chorioretinopathy: An Exploratory Retrospective Study},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {21},
  pages = {8482},
  doi = {10.3390/jcm15218482}
}
Kostenlos starten →